“We want to run a phase III study in Kazakhstan because of (1) cost attractiveness, (2) no competing studies at sites in Kazakhstan and we also want to build relationships with key opinion leaders. We also heard that regulatory review times are competitive. We want to find sites that have trained physicians and get our study up and going within 6 months.”

Kazakhstan has all of the advantages mentioned. Many sites have good infrastructure. There are physicians and hospital sites familiar with Good Clinical Practice and international trial standards, but one needs to be selective in choosing appropriate trial sites. We can help navigate regulatory submissions, identify clinician investigators and initiate and monitor phase II, III and IV pharmaceutical studies.

“We want to explore the possibilities of bringing high cost pharmaceutical products for out-of-pocket purchase in Kazakhstan. We need interview data from high level health care leaders, physician leaders, pharmacists and patients. We don’t have staff in Kazakhstan and need a competent consultant to lead and administer this discrete project.”

Kazakhstan’s economy is growing at a substantial rate (~4% per annum) and with this growth, a new market for high-cost innovative pharmaceuticals has emerged. In this instance, through our network of contacts, we can identify drug reimbursement processes, key motivating factors and describe the important public/private interface and through key opinion leaders we can gather qualitative and quantitative data on which to base market entry decisions.